Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312286 · ClinicalTrials.gov registry record · Phase 2
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 538
- Enrollment target
NCT00312286 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 538 participants.
The verdict
NCT00312286, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 538 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
Interventions
- DRUG 851B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312286
The ClinicalTrials.gov registry entry for NCT00312286 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 538 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 851B is the first listed.
NCT00312286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00312286 about?
NCT00312286 is a clinical study titled "Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.". The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
What is the current status of trial NCT00312286?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 538 participants. The study started on 2006-04. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00312286?
The interventions under investigation include: 851B (DRUG).
Who is sponsoring clinical trial NCT00312286?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.